

Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017

<https://marketpublishers.com/r/HE6FB2A2F17EN.html>

Date: November 2017

Pages: 0

Price: US\$ 3,250.00 (Single User License)

ID: HE6FB2A2F17EN

Abstracts

This report can be delivered to the clients within 25 Hours

DelveInsight's, "Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017" report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action. The report provides information on all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. Furthermore, the report also contains detailed information of marketed products along with historical and forecasted sales.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

The report comprehensively includes:

In-depth analysis of the 28+ pipeline assets and 5 marketed products

Therapeutic assessment by molecule type, route of administration, monotherapy and combination products

Licensing, Deals and Patent details (marketed and pipeline) related to HDAC inhibitors are also covered

Insights on marketed products including detailed marketed product profiles.
Also, includes Historical and Forecasted sales for Marketed products

Information on various technologies involved in the development of pipeline therapeutics along with drug designations is also provided

Contents

- Executive Summary
- Overview
- Competitive Landscape
- Collaboration
- Technology
- Designation
- Active Pipeline coverage by Indication
- Marketed and Pipeline Drugs
- Marketed Drug Profiles
- Farydak: Novartis
 - Product Description
 - Regulatory Milestones
 - Research and Development
 - Other Clinical Activities
 - Product Development Activities
- Farydak Global Sales
- Farydak Analyst Insights
- Beleodaq: Spectrum Pharmaceuticals
 - Product Description
 - Regulatory Milestones
 - Research and Development
 - Other Clinical Activities
 - Product Development Activities
- Beleodaq Global Sales
- Beleodaq Analyst Insights
- Epidaza: Chipscreen Bioscience
 - Product Description
 - Regulatory Milestones
 - Research and Development
 - Other Clinical Activities
 - Product Development Activities
- Epidaza Analyst Insights
- Zolinza: Merck
 - Product Description
 - Regulatory Milestones
 - Research and Development
 - Other Clinical Activities

Product Development Activities
Zolinza Global Sales
Zolinza Analyst Insights
Istodax: Gloucester Pharmaceuticals
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Istodax Global Sales
Istodax Analyst Insights
Market Positioning of HDAC Inhibitors
HDAC Inhibitors Market Evaluation
HDAC Inhibitors Class Share Evaluation
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Entinostat: Syndax Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Pracinostat: MEI Pharma
Product Description
Research and Development
Product Development Activities
Givinostat: Italfarmaco
Product Description
Research and Development
Product Development Activities
Mid-Stage Products (Phase II)
Comparative Analysis
Mocetinostat: Mirati Therapeutic
Product Description
Research and Development
Product Development Activities
Quisinostat: Janssen
Product Description
Research and Development

Product Development Activities
VRx-3996: Viracta Therapeutics
Product Description
Research and Development
Product Development Activities
Sulforadex: Evgen Pharma
Product Description
Research and Development
Product Development Activities
CHR 5154: Chroma Therapeutics
Product Description
Research and Development
Product Development Activities
CUDC 907: Curis
Product Description
Research and Development
Product Development Activities
Ricolinostat: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Remetinostat: TetraLogic Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Abexinostat: Celera Genomics Group
Product Description
Research and Development
Product Development Activities
Resminostat: 4SC
Product Description
Research and Development
Product Development Activities
FRM 0334: FORUM Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis

Citarinostat: Celgene Corporation

Product Description

Research and Development

Product Development Activities

AR-42: Arno Therapeutics

Product Description

Research and Development

Product Development Activities

EDO S101: Mundipharma International

Product Description

Research and Development

Product Development Activities

Pre-clinical Products

Comparative Analysis

PCI-34051: Pharmacyclics

Product Description

Research and Development

Product Development Activities

HG 3001: HitGen

Product Description

Research and Development

Product Development Activities

CG-1255: CircaGen Pharmaceutical

Product Description

Research and Development

Product Development Activities

CG-1521: CircaGen Pharmaceutical

Product Description

Research and Development

Product Development Activities

Trichostatin A: Errant Gene Therapeutics

Product Description

Research and Development

Product Development Activities

QTX-125: Quimatryx

Product Description

Research and Development

Product Development Activities

QTX-153: Quimatryx

Product Description
Research and Development
Product Development Activities
ACY 1083: Regenacy Pharmaceuticals
Product Description
Research and Development
Product Development Activities
ACY-738: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Institutional Products
Inactive Products
Comparative Analysis
Market Drivers and Barriers
Appendix

List Of Tables

LIST OF TABLES

Table 1: Active Pipeline Coverage by Indication

Table 2: Marketed and Pipeline HDAC Inhibitors

Table 3: Total Products for HDAC Inhibitors

Table 4: Late Stage Products (Phase III)

Table 5: Mid Stage Products (Phase II)

Table 6: Pre-clinical Products

Table 7: Assessment by Monotherapy Products

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Dormant Products

Table 13: Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1: Structure of HDAC Inhibitors
- Figure 2: Mechanism of HDAC Inhibitors
- Figure 3: Marketed and Pipeline HDAC Inhibitors
- Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
- Figure 5: Market Evolution (2015-2023)
- Figure 6: Total Active Products for HDAC Inhibitors
- Figure 7: Total Products for HDAC Inhibitors
- Figure 8: Late Stage Products (Phase III)
- Figure 9: Entinostat Forecasted Sales (2019-2023)
- Figure 10: Mid Stage Products (Phase II)
- Figure 11: Early Stage Products (Phase I)
- Figure 12: Pre-clinical Products
- Figure 13: Assessment by Monotherapy Products
- Figure 14: Assessment by Route of Administration
- Figure 15: Assessment by Stage and Route of Administration
- Figure 16: Assessment by Molecule Type
- Figure 17: Assessment by Stage and Molecule Type
- Figure 18: Inactive Products

I would like to order

Product name: Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017

Product link: <https://marketpublishers.com/r/HE6FB2A2F17EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE6FB2A2F17EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

